Related Experiment Video

Updated: Jun 4, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

[Warfarin combined with blood platelet inhibition]

Harald Vik-Mo1

  • 1Hjertemedisinsk avdeling, St. Olavs hospital. harald.vik-mo@ntnu.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|February 10, 2011
PubMed

Insights

Dual antiplatelet therapy combined with oral anticoagulation is crucial but lacks trial guidance. Triple therapy reduces thrombosis but increases bleeding risk, necessitating careful management strategies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Context:

  • Coronary stent implantation and acute coronary syndrome (ACS) management require dual antiplatelet therapy (acetylsalicylic acid and a thienopyridine).
  • Many patients require concurrent oral anticoagulation, creating a complex therapeutic scenario.
  • Current treatment guidelines lack prospective randomized trial data for this patient population.

Purpose:

  • To review current practices and provide guidance on managing patients requiring both dual antiplatelet therapy and oral anticoagulation.
  • To highlight the risks and benefits of triple antithrombotic therapy (acetylsalicylic acid, clopidogrel, and warfarin).

Summary:

  • Triple antithrombotic therapy is commonly used, balancing the reduced risk of thrombosis and thromboembolism against an increased risk of bleeding.
  • Key strategies to mitigate complications include careful International Normalized Ratio (INR) monitoring, minimizing triple therapy duration, utilizing radial access, and employing bare metal stents.

Impact:

  • Provides evidence-based recommendations for optimizing antithrombotic therapy in high-risk cardiovascular patients.
  • Aims to reduce bleeding complications while maintaining efficacy in preventing thrombotic events.
  • Informs clinical decision-making in the absence of definitive randomized controlled trials.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...